Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,720,000 shares, a drop of 15.5% from the January 15th total of 3,220,000 shares. Based on an average daily volume of 477,000 shares, the short-interest ratio is currently 5.7 days. Currently, 24.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on JSPR shares. BMO Capital Markets began coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. Royal Bank of Canada reduced their price target on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. UBS Group began coverage on shares of Jasper Therapeutics in a research note on Thursday. They set a “buy” rating and a $38.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, HC Wainwright cut their price target on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $64.44.

Jasper Therapeutics Stock Down 1.9 %

JSPR traded down $0.12 on Monday, reaching $6.08. The company had a trading volume of 477,987 shares, compared to its average volume of 671,338. The stock has a 50-day moving average price of $12.46 and a 200-day moving average price of $17.43. The stock has a market capitalization of $91.21 million, a PE ratio of -1.28 and a beta of 2.11. Jasper Therapeutics has a 1 year low of $4.55 and a 1 year high of $31.01.

Institutional Trading of Jasper Therapeutics

A number of large investors have recently made changes to their positions in JSPR. Jane Street Group LLC acquired a new position in Jasper Therapeutics during the third quarter worth approximately $251,000. Samsara BioCapital LLC grew its position in shares of Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares during the last quarter. Barclays PLC increased its holdings in shares of Jasper Therapeutics by 320.7% in the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after acquiring an additional 12,308 shares during the period. Wellington Management Group LLP purchased a new stake in Jasper Therapeutics in the 3rd quarter valued at $447,000. Finally, Ally Bridge Group NY LLC boosted its stake in Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the period. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.